Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy - Slideshow (NASDAQ:ATHE) 2026-05-02
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Le titre d’Alterity Therapeutics grimpe après des données positives d’essai sur l’AMS présentées lors d’une conférence
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Albemarle (NYSE:ALB), Above Food Ingredients (NASDAQ:ABVE)